New discoveries in the genetics and genomics of systemic juvenile idiopathic arthritis
- PMID: 38641907
- PMCID: PMC11303111
- DOI: 10.1080/1744666X.2024.2345868
New discoveries in the genetics and genomics of systemic juvenile idiopathic arthritis
Abstract
Introduction: Systemic juvenile idiopathic arthritis (sJIA) is a severe inflammatory condition with onset in childhood. It is sporadic, but elements of its stereotypical innate immune responses are likely genetically encoded by both common variants with small effect sizes and rare variants with larger effects.
Areas covered: Genomic investigations have defined the unique genetic architecture of sJIA. Identification of the class II HLA locus as the strongest sJIA risk factor for the first time brought attention to T lymphocytes and adaptive immune mechanisms in sJIA. The importance of the human leukocyte antigen (HLA) locus was reinforced by recognition that HLA-DRB1*15 alleles are strongly associated with development of drug reactions and sJIA-associated lung disease (sJIA-LD). At the IL1RN locus, genetic variation relates to both risk of sJIA and may also predict non-response to anakinra. Finally, rare genetic variants may have critical roles in disease complications, such as homozygous LACC1 mutations in families with an sJIA-like illness, and hemophagocytic lymphohistiocytosis (HLH) gene variants in some children with macrophage activation syndrome (MAS).
Expert opinion: Genetic and genomic analysis of sJIA holds great promise for both basic discovery of the course and complications of sJIA, and may help guide personalized medicine and therapeutic decision-making.
Keywords: Macrophage activation syndrome; genetics; genomics; lung disease; still’s disease.
Similar articles
-
Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants.Arthritis Rheumatol. 2024 Jan;76(1):119-129. doi: 10.1002/art.42656. Epub 2023 Nov 6. Arthritis Rheumatol. 2024. PMID: 37471469
-
HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15970-5. doi: 10.1073/pnas.1520779112. Epub 2015 Nov 23. Proc Natl Acad Sci U S A. 2015. PMID: 26598658 Free PMC article.
-
Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches.Clin Immunol. 2015 Jul;159(1):72-83. doi: 10.1016/j.clim.2015.04.018. Epub 2015 May 6. Clin Immunol. 2015. PMID: 25956529 Review.
-
Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.Genes Immun. 2012 Jun;13(4):289-98. doi: 10.1038/gene.2012.3. Epub 2012 Mar 15. Genes Immun. 2012. PMID: 22418018 Review.
-
Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment.Curr Opin Rheumatol. 2018 Sep;30(5):514-520. doi: 10.1097/BOR.0000000000000526. Curr Opin Rheumatol. 2018. PMID: 29870499 Review.
References
-
- Packham JC HM. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002;41:1428–35. - PubMed
-
- Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004. Feb;31(2):390–2. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials